671 related articles for article (PubMed ID: 33983621)
1. Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.
Qu Y; Lipkovich I
Ther Innov Regul Sci; 2021 Sep; 55(5):984-988. PubMed ID: 33983621
[TBL] [Abstract][Full Text] [Related]
2. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.
Ratitch B; Bell J; Mallinckrodt C; Bartlett JW; Goel N; Molenberghs G; O'Kelly M; Singh P; Lipkovich I
Ther Innov Regul Sci; 2020 Mar; 54(2):324-341. PubMed ID: 32072573
[TBL] [Abstract][Full Text] [Related]
3. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
[TBL] [Abstract][Full Text] [Related]
4. Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
Qu Y; Shurzinske L; Sethuraman S
Pharm Stat; 2021 Mar; 20(2):314-323. PubMed ID: 33098267
[TBL] [Abstract][Full Text] [Related]
5. Incorporating estimands into clinical trial statistical analysis plans.
Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
[TBL] [Abstract][Full Text] [Related]
6. Implementation of tripartite estimands using adherence causal estimators under the causal inference framework.
Qu Y; Luo J; Ruberg SJ
Pharm Stat; 2021 Jan; 20(1):55-67. PubMed ID: 33442928
[TBL] [Abstract][Full Text] [Related]
7. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.
Rehal S; Cro S; Phillips PP; Fielding K; Carpenter JR
Clin Trials; 2023 Oct; 20(5):497-506. PubMed ID: 37277978
[TBL] [Abstract][Full Text] [Related]
8. Hypothetical Estimands in Clinical Trials: A Unification of Causal Inference and Missing Data Methods.
Olarte Parra C; Daniel RM; Bartlett JW
Stat Biopharm Res; 2023; 15(2):421-432. PubMed ID: 37260584
[TBL] [Abstract][Full Text] [Related]
9. Estimands in practice: Bridging the gap between study objectives and statistical analysis.
Phillips A; Clark T
Pharm Stat; 2021 Jan; 20(1):68-76. PubMed ID: 32893473
[TBL] [Abstract][Full Text] [Related]
10. Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.
Mitroiu M; Teerenstra S; Oude Rengerink K; Pétavy F; Roes KCB
Pharm Stat; 2022 Sep; 21(5):1037-1057. PubMed ID: 35678545
[TBL] [Abstract][Full Text] [Related]
11. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
Jin M; Liu G
Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
[TBL] [Abstract][Full Text] [Related]
12. Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric Disorder.
Polverejan E; O'Kelly M; Hefting N; Norton JD; Lim P; Walton MK
Ther Innov Regul Sci; 2023 Sep; 57(5):911-939. PubMed ID: 37244885
[TBL] [Abstract][Full Text] [Related]
13. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.
Morga A; Latimer NR; Scott M; Hawkins N; Schlichting M; Wang J
Value Health; 2023 Feb; 26(2):234-242. PubMed ID: 36150999
[TBL] [Abstract][Full Text] [Related]
14. Application of estimand framework in ICH E9 (R1) to safety evaluation.
Wang X; Yang P; Yuan SS; Wang WWB
J Biopharm Stat; 2023 Jul; 33(4):476-487. PubMed ID: 36951445
[TBL] [Abstract][Full Text] [Related]
15. Use of the Estimand Framework to Manage the Disruptive Effects of COVID-19 on Stroke Clinical Trials.
Yassi N; Hayward KS; Campbell BCV; Churilov L
Stroke; 2021 Nov; 52(11):3739-3747. PubMed ID: 34587797
[TBL] [Abstract][Full Text] [Related]
16. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.
Ratitch B; Goel N; Mallinckrodt C; Bell J; Bartlett JW; Molenberghs G; Singh P; Lipkovich I; O'Kelly M
Ther Innov Regul Sci; 2020 Mar; 54(2):370-384. PubMed ID: 32072586
[TBL] [Abstract][Full Text] [Related]
17. Rethinking intercurrent events in defining estimands for tuberculosis trials.
Pham TM; Tweed CD; Carpenter JR; Kahan BC; Nunn AJ; Crook AM; Esmail H; Goodall R; Phillips PP; White IR
Clin Trials; 2022 Oct; 19(5):522-533. PubMed ID: 35850542
[TBL] [Abstract][Full Text] [Related]
18. Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice.
Mallinckrodt CH; Bell J; Liu G; Ratitch B; O'Kelly M; Lipkovich I; Singh P; Xu L; Molenberghs G
Ther Innov Regul Sci; 2020 Mar; 54(2):353-364. PubMed ID: 32072593
[TBL] [Abstract][Full Text] [Related]
19. Connecting Instrumental Variable methods for causal inference to the Estimand Framework.
Bowden J; Bornkamp B; Glimm E; Bretz F
Stat Med; 2021 Nov; 40(25):5605-5627. PubMed ID: 34288021
[TBL] [Abstract][Full Text] [Related]
20. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
